Veracyte, Inc. (VCYT) income statement
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3029% below fair value
$25.04−0.53 (-2.07%)
Close on Nov 19, 2026Market cap $2.01BP/E 17.9Yield –
Veracyte, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 71.7%
- Operating margin
- 18.8%
- Net margin
- 20.4%
- Return on equity, FY2025
- 5.3%
Financial strength
- Current ratio
- 9.16
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 477.4%
Valuation
- P/E ratio
- 17.9
- Price to sales
- 3.58
- Price to book
- 1.45
- Dividend yield
- –
See a number that looks wrong?